Cargando…

Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases

BACKGROUND: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are lacking and knowledge about individual ATI dynamics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grasmeier, Melina K., Langmann, Anna F., Langmann, Peter, Treiber, Matthias, Thaler, Markus A., Luppa, Peter B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381421/ https://www.ncbi.nlm.nih.gov/pubmed/34434255 http://dx.doi.org/10.1177/17562848211037849

Ejemplares similares

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Microglia and Inflammatory Responses in Diabetic Retinopathy
por: Kinuthia, Urbanus Muthai, et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Effect of firearms legislation on suicide and homicide in Canada from 1981 to 2016
por: Langmann, Caillin
Publicado: (2020)

Cytokine signaling as key regulator of pathological angiogenesis in the eye
por: Langmann, Thomas
Publicado: (2021)

Vulnerability, ageism, and health: is it helpful to label older adults as a vulnerable group in health care?
por: Langmann, Elisabeth
Publicado: (2022)

Mass homicide by firearm in Canada: Effects of legislation
por: Langmann, Caillin
Publicado: (2023)

Blockade of microglial adenosine A2A receptor impacts inflammatory mechanisms, reduces ARPE-19 cell dysfunction and prevents photoreceptor loss in vitro
por: Madeira, M. H., et al.
Publicado: (2018)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration
por: Scholz, Rebecca, et al.
Publicado: (2015)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Gut flora connects obesity with pathological angiogenesis in the eye
por: Scholz, Rebecca, et al.
Publicado: (2016)

Anti‐VEGF‐A/ANG2 combotherapy limits pathological angiogenesis in the eye: a replication study
por: Wolf, Anne, et al.
Publicado: (2019)

IFN-β signaling dampens microglia reactivity but does not prevent from light-induced retinal degeneration
por: Behnke, Verena, et al.
Publicado: (2020)

Leaving no one behind: successful ageing at the intersection of ageism and ableism
por: Langmann, Elisabeth, et al.
Publicado: (2023)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Atomic Force Microscopy Application for the Measurement of Infliximab Concentration in Healthy Donors and Pediatric Patients with Inflammatory Bowel Disease
por: Curci, Debora, et al.
Publicado: (2022)

Indole-3-carbinol regulates microglia homeostasis and protects the retina from degeneration
por: Khan, Amir Saeed, et al.
Publicado: (2020)

Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases
por: Malíčková, Karin, et al.
Publicado: (2012)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
por: Pękala, Anna, et al.
Publicado: (2021)

Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease
por: Phillips, Jennifer, et al.
Publicado: (2023)

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
por: Berends, Sophie E., et al.
Publicado: (2019)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Microglia Activation and Immunomodulatory Therapies for Retinal Degenerations
por: Rashid, Khalid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tc01nd4a90drhmbbqscikc8n1a